Get the Stockscreener App
11.45
0.35%
-0.04
After Hours:
11.33
-0.12
-1.05%
Helus Pharma Inc stock is traded at $11.45, with a volume of 1.94M.
It is down -0.35% in the last 24 hours and up +70.90% over the past month.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
See More
Previous Close:
$11.49
Open:
$11.62
24h Volume:
1.94M
Relative Volume:
1.40
Market Cap:
$709.72M
Revenue:
-
Net Income/Loss:
$-148.00M
P/E Ratio:
-2.5847
EPS:
-4.4299
Net Cash Flow:
$-135.66M
1W Performance:
+3.15%
1M Performance:
+70.90%
6M Performance:
+88.01%
1Y Performance:
+0.00%
1-Day Range:
$11.38
$11.95
1-Week Range:
$9.835
$11.95
52-Week Range:
$3.76
$11.95
Helus Pharma Inc Stock (HELP) Company Profile
Compare HELP vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HELP
Helus Pharma Inc
|
11.45 | 712.20M | 0 | -148.00M | -135.66M | -4.4299 |
VRTX
Vertex Pharmaceuticals Inc
|
516.44 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.97 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
856.94 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
202.00 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
356.01 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Helus Pharma Inc Stock (HELP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-13-26 | Initiated | TD Cowen | Buy |
| Feb-02-26 | Initiated | Jefferies | Buy |
| Mar-13-25 | Initiated | Guggenheim | Buy |
| Nov-19-21 | Downgrade | Maxim Group | Buy → Hold |
Helus Pharma Inc Stock (HELP) Latest News
Cybin Stock Builds Bullish Momentum as Clinical Catalysts Strengthen the HELP Outlook - kalkine.ca
Helus Pharma at Canaccord Genuity growth conference: phase iii test looms - Investing.com Canada
Adage Capital reports 5.29% Cybin Inc. (HELP) ownership, 3.29M shares - Stock Titan
Cybin D/B/A Helus Pharma (HELP) Stock Price, News, Quote & History - Yahoo! Finance Canada
FDA Fast-Tracks Psychedelic Research After Trump’s Executive Order — CMPS, HELP Stocks Gain - Stocktwits
Helus Pharma (HELP) CEO to Join Canaccord Genuity Growth Conference Fireside Chat - Stock Titan
Cybin’s Helus Pharma to join Canaccord Genuity Annual Growth Conference fireside chat - Bitget
Helus Pharma to Participate at the Canaccord Genuity 46th Annual Growth Conference in BostonMon, 08/10/202612:00 - Helus Pharma
Cybin (HELP) Names New CEO, Is The Stock Still Cheap? - Yahoo! Finance Canada
Cybin (HELP) Is Up 33.1% After Hiring Helus Veteran Michael Halstead As CEO – Has The Bull Case Changed? - Yahoo Finance
Cybin (Helus Pharma, HELP) Leaps 14% Ahead of Pivotal Depression Trial Data - kalkine.ca
Could Helus Pharma’s New CEO Reframe Cybin’s (HELP) Path From Clinical Trials To Commercial Scale? - simplywall.st
Helus Pharma Shares Rise After Appointing New CEO - Moomoo
A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 Readout - The Manila Times
A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies ... - Caledonian Record
A CEO With a Proven Track Record of Success in Growing and - GlobeNewswire
Helus Pharma appoints Michael Halstead as chief executive - Investing.com
Helus Pharma Appoints Michael Halstead as Chief Executive Officer - The Manila Times
Helus Pharma appoints Michael Halstead as chief executive By Investing.com - Investing.com India
Helus Pharma (HELP.NE) Names Michael Halstead CEO Ahead of Phase 3 HLP003 Data Readout - kalkine.ca
HELP Stock Price and Chart — NEO:HELP - tradingview.com
HELP Initiated Coverage by Wells Fargo -- Rating Set to Overweig - GuruFocus
HELP Initiated Coverage by Wells Fargo -- Rating Set to Overweight - GuruFocus
Helus Pharma Price Target Announced at $16.00/Share by Wells Fargo - Moomoo
Cybin (CYBN) Stock Fair Value Moves Lower As Analysts Rework Psychedelic Sector Assumptions - Yahoo Finance
Cybin D/B/A Helus Pharma (HELP.NE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Helus Pharma (HELP) and Nektar Therapeutics (NKTR) - The Globe and Mail
Cybin D/B/A Helus Pharma (HELP) stock price, news, quote and history - Yahoo Finance UK
Cybin D/B/A Helus Pharma (HELP.NE) stock price, news, quote and history - Yahoo Finance UK
HELP: Helus Pharma Inc. Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
symbol__ Stock Quote Price and Forecast - CNN
H.C. Wainwright reiterates Helus Pharma stock rating on trial enrollment By Investing.com - Investing.com Canada
Helus Pharma Inc. (HELP) News, Articles, Events & Latest Updates - Stocktwits
Helus Pharma (HELP) Achieves Enrollment Milestone in Phase 3 Stu - GuruFocus
HELP Stock Surges To Over 6-Month Highs Led By Crucial Phase 3 Milestone – Retail Expects It To Hit Fresh 52-Week Highs - Yahoo Finance
Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of H - GuruFocus
Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule - Nasdaq
Helus Pharma stock jumps on Phase 3 enrollment completion By Investing.com - Investing.com Canada
A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening - Cantech Letter
Helus Pharma completes enrollment in Phase 3 tr... - Pluang
Chief Financial Officer Greg Cavers Sold A Bunch Of Shares In Cybin - simplywall.st
Cybin (HELP) Advances Psychedelic Depression Drug to Phase 3 Amid Fresh Funding – What Really Matters? - simplywall.st
Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time - Finansavisen
Cybin (HELP) Is Up 6.2% After Advancing HLP003 To Phase 3 And Raising US$50 Million - Yahoo Finance
Helus Pharma (Nasdaq: HELP) closes US$50M underwritten share offering - Stock Titan
Is Cybin D/B/A Helus Pharma (HELP) Stock a Psychedelic Medicine Opportunity Ahead of HLP003 Trial Results? - Yahoo Finance
Helus Pharma Inc Stock (HELP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.03%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):